GILD241227C102000
- 0.23
- 0.000.00%
Gilead Sciences Newsroom
Gilead (GILD.US) has received approval for the long-acting HIV treatment "Lenacapavir" to be marketed in China.
The official NMPA website shows that Gilead's (GILD.US) HIV therapy, Lenacapavir tablets and Lenacapavir injection, has received marketing approval.
Is Gilead Sciences, Inc. (GILD) the Best Pharma Dividend Stocks to Buy In 2024?
Market Falling Monday, With Few Santa Clause 'Rally' Days Left | Live Stock
Morgan Stanley: Personalized cancer vaccines and ADCs will become the main catalysts in the oncology treatment Industry by 2025.
Morgan Stanley stated in a recent research report that personalized cancer vaccines and antibody-drug conjugates (ADCs) will become one of the major innovations in cancer biotechnology next year.
Gilead Buys $20.1 Million of Assembly Biosciences Stock -- Barrons.com
Here Are Morgan Stanley's Key Oncology Catalysts for 2025
Weekly Buzz: So far, Santa is Letting us Down
Friday Market Pulls Back, Led by Mag Seven Decline | Live Stock
Jim Cramer on Gilead Sciences, Inc. (GILD): 'I Don't Think The Business Is Worth As Much As The Stock Is Selling'
Gilead Sciences, Inc. (GILD) Is Attracting Investor Attention: Here Is What You Should Know
Assembly Biosciences Says Antiviral Drug Shows 'Encouraging' Phase 1 Results
Assembly Bio Spikes After Early-stage Data for Gilead-partnered Hep B Therapy
Here's How You Can Earn $100 In Passive Income By Investing In Gilead Sciences Stock
Gilead Sciences (GILD) Made Big Announcements in Q3
SA Asks: Which Big Pharmas Are Likely to Announce Big M&A Deals?
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
Gilead Stock Gains 15.4% in a Year: Should You Buy, Sell or Hold?
Gilead Sciences to Present at Upcoming Investor Conference
Friday Opens With Falling Prices, but Market Turns Around | Live Stock
19% Of This Gilead Sciences Insider's Holdings Were Sold